ZLDPF Zealand Pharma A/S

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Press Release – No. 15 / 2025

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results

Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 13, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the third quarter of 2025.

Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.

To receive telephone dial-in information and a unique personal access PIN, please register at . The live listen-only audio webcast of the call and accompanying slides presentation will be accessible at .  Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at .

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Neshat Ahmadi (Investors)

Investor Relations Manager

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

Email:



EN
06/11/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma CMD key takeaways

Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...

ZLDPF ZEALAND PHARMA A/S
3h / 27m 3h / 27m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma increases its share capital as a result of the exercise...

Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...

14h / 35m 1 EN
Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
XIOR Xior Student Ho...
IBAB Ion Beam Applic... ... (+9)

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

XIOR XIOR STUDENT HOUSING N.V.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
ZLDPF ZEALAND PHARMA A/S
ONTEX ONTEX GROUP N.V.
ARG ARGAN SA
AKZA AKZO NOBEL N.V.
SEQUA SEQUANA MEDICAL
DEME DEME GROUP NV
12/11/25 December 11, 2025 1 EN
Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...

Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...

ZLDPF ZEALAND PHARMA A/S
12/11/25 December 11, 2025 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch